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Themammalian target of rapamycin (mTOR) signaling pathway is amaster regulator of cell growth andmeta-
bolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as can-
cer, diabetes, obesity, neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of
mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism
of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and
the potential utility of combination therapy with rapamycin.An Introduction to Rapamycin: History and Mechanism
of Action
Rapamycin was initially discovered as an antifungal metabolite
produced by Streptomyces hygroscopicus from a soil sample
of Easter Island (also known as Rapa Nui). Subsequently, rapa-
mycin was found to possess immunosuppressive and antiproli-
ferative properties in mammalian cells, spurring an interest in
identifying the mode of action of rapamycin. Rapamycin was
shown to be a potent inhibitor of S6K1 activation, a serine/thre-
onine kinase activated by a variety of agonists (Chung et al.,
1992; Kuo et al., 1992; Price et al., 1992) and an important medi-
ator of PI3 kinase signaling (Chung et al., 1994). Concurrently,
the target of rapamycin (TOR) was identified in yeast and animal
cells (Laplante and Sabatini, 2012; Loewith and Hall, 2011).
Rapamycin forms a gain-of-function complex with the 12 kDa
FK506-binding protein (FKBP12), and this complex binds and
specifically acts as an allosteric inhibitor of mammalian TOR
(mTOR, also known as mechanistic TOR) complex 1 (mTORC1).
Biochemical and genetic analysis of mTOR has demonstrated
that it is present in two functionally distinct complexes. The core
components of mTORC1 consist of mTOR, mammalian lethal
with sec-13protein 8 (mLST8), and regulatory-associated protein
of TOR (raptor). Additional components include DEP-domain-
containing mTOR-interacting protein (DEPTOR) and proline-rich
Akt substrate 40 kDa (PRAS40). ThemTORcomplex 2 (mTORC2)
core is composed of mTOR, rapamycin insensitive companion of
mTOR (rictor), stress-activated protein kinase-interacting protein
1 (mSIN1), andmLST8. Protein observedwith rictor 1/2 (protor 1/
2) and DEPTOR are additional regulatory components (Cornu
et al., 2013; Laplante and Sabatini, 2012). S6 kinase 1 (S6K1)
and eukaryotic inhibition factor eIF4E binding protein 1 (4E-
BP1) are two well-characterized substrates of mTORC1 (Ma
and Blenis, 2009). Only mTORC1 is acutely sensitive to inhibition
by rapamycin. However, long-term exposure to rapamycin in-
hibits mTORC2 in some cell types by sequestering newly synthe-
sized mTOR molecules (Laplante and Sabatini, 2012).
Over the past two decades, significant progress has been
made in understanding the complexity of mTORC1 regulation
and its roles in disease. mTORC1 is a signal integrator respond-
ing tomultiple signals from growth factors, nutrients, energy, and
oxygen status to control processes that are required for cell
growth and proliferation, including mRNA biogenesis, protein,
lipid and nucleotide synthesis, energy metabolism, and auto-phagy (Figure 1). Improper regulation of the mTORC1 pathway
is frequently found in cancers as well as in several genetic disor-
ders. Recent evidence indicates that mTORC1 is also an impor-
tant modulator for aging and age-related diseases (Johnson
et al., 2013a). In contrast to mTORC1, much less is known about
mTORC2. mTORC2 participates in cell survival via activation of
Akt and SGK1. mTORC2 also regulates organization of the actin
cytoskeleton through activation of PKCa, paxillin and small
GTPases, Rho, and Rac (Laplante and Sabatini, 2012).
Effects of Rapamycin in Cancer
Increased activation of mTORC1 is observed in numerous
human cancers due to gain-of-function mutations in oncogenes
(i.e., PI3K, AKT, or Ras) and/or loss-of-function mutations in
tumor suppressors (i.e., PTEN, LKB1, or TSC1/2), upstream reg-
ulators of mTORC1. These mutations provide cancer cells with
a selective growth advantage in comparison to normal cells
(Menon and Manning, 2008). In order to meet the high demands
of proliferation, cancer cells often have fundamental alterations
in nutrient uptake and energy metabolism, processes that are
directly controlled by the mTORC1 pathway. Accordingly, in
addition to driving protein synthesis, oncogenic activation of
mTORC1 promotes a gene expression program that is involved
in cancer cell metabolic reprogramming. Activation of mTORC1
promotes glycolysis via upregulation of hypoxia-inducible factor
alpha (HIF1a) and c-Myc, stimulates lipid biosynthesis and the
pentose phosphate pathway through sterol regulatory element
binding protein 1 (SREBP-1) (Yecies and Manning, 2011), and
positively controls glutamine metabolism by SIRT4 repression
(Csibi et al., 2013). Thus, drugs that selectively target mTORC1,
like rapamycin, are expected to impair cancer metabolism and
are considered promising anticancer therapies.
The poor solubility and pharmacokinetics of rapamycin trig-
gered the development of several rapamycin analogs (rapalogs).
Two water-soluble derivatives of rapamycin, temsirolimus and
everolimus, were approved by the Food and Drug Administration
(FDA) in 2007 and 2009, respectively, for the treatment of
advanced renal cancer carcinoma (RCC). In 2011, the FDA
approved the use of everolimus for patients with progressive
neuroendocrine tumors of pancreatic origin (PNET). Additionally,
temsirolimus was evaluated in several clinical trials for the treat-
ment of advanced neuroendocrine carcinoma (NEC), advanced
or recurrent endometrial cancer, and relapsed or refractoryCell Metabolism 19, March 4, 2014 ª2014 Elsevier Inc. 373
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Figure 1. The Two mTOR Complexes and the Regulation of Key Cellular Processes
mTOR exists in two functionally distinct complexes, termed mTORC1 and mTORC2. mTORC1 integrates multiple signals from growth factors, oxygen, energy
levels, and nutrients such as amino acids to promote cell growth and proliferation by activation of anabolic processes such as protein, lipid, and nucleotide
synthesis; stimulation of energy metabolism such as glycolysis and glutaminolysis; and inhibition of catabolic process such as autophagy. Unlike mTORC1,
mTORC2 only responds to growth factors and regulates actin/cytoskeleton organization and cell survival through the pathways as shown above. Rapamycin
acutely inhibits mTORC1, whereas chronic exposure to rapamycin can also inhibit mTORC2.
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2009). Moreover, a few trials of everolimus were conducted in
patients with advanced gastric cancer, advanced non-small-
cell lung cancer (NSCLC), and advanced hepatocellular carci-
noma. Ridaforolimus, a rapamycin analog, was also examined
in clinical trials for advanced bone and soft-tissue sarcomas as
well as a variety of advanced solid tumors (Wander et al.,
2011). Overall, however, rapalogs have only achieved modest
effects in major solid tumors in the clinic. The reasons for the
limited clinical success of rapalogs have not been established
but are likely related to the large number of mTORC1-regulated
negative feedback loops that suppress upstream signaling sys-
tems such as activation of receptor tyrosine kinases (RTKs),
PI3K-Akt signaling, and Ras-ERK pathway and which can be
reactivated with rapamycin (discussed more extensively below).
In order to overcome these limitations, alternative strategies
have been explored in the past few years. For instance, a number
of ATP-competitive mTOR inhibitors have been developed,
blocking both mTORC1 and mTORC2 activity. Due to high-
sequence homology shared between mTOR and PI3K, some
compounds that were originally identified as PI3K inhibitors
were later shown to inhibit mTOR. Unlike rapamycin, which is a
specific allosteric inhibitor of mTORC1, these ATP-competitive
inhibitors target the catalytic site and prevent the feedback-
mediated PI3K/Akt activation (described below), and therefore
can potentially offer broader, more potent, and sustained
mTOR inhibition (Benjamin et al., 2011) (Figure 2).374 Cell Metabolism 19, March 4, 2014 ª2014 Elsevier Inc.Effects of Rapamycin in Lymphangioleiomyomatosis,
Tuberous Sclerosis Complex, and Neurological
Diseases
Lymphangioleiomyomatosis (LAM) is a rare lung disease charac-
terized by abnormal proliferation of smooth muscle-like cells.
Infiltration of the lungwith these cells by amysteriousmechanism
referred to as benign metastasis can result in an anti-inflamma-
tory response, cyst formation, and ultimately respiratory failure
(Yu and Henske, 2010). LAM arises almost exclusively in women
during their childbearing age and occurs either as an isolated dis-
order (sporadic LAM) or in association with tuberous sclerosis
complex (TSC). TSC is a genetic disorder characterized by the
development of benignhamartomatous tumors involvingmultiple
organ systems. Both LAM and TSC are caused by loss-of-func-
tion mutations in the TSC genes (TSC1 or TSC2), whose protein
products function as a complex to inhibit the activity ofmTORC1.
Thus, hyperactive mTORC1 signaling is directly linked to the
unregulated cell growth that drives the clinical manifestations.
Hence, the use of mTORC1 inhibitors could potentially benefit
LAMandTSCpatients. In the past few years, several clinical trials
wereconducted to examine theefficacy and safety of rapamycin-
based therapy. For example, in 2011, McCormack et al. (2011)
reported a double-blind, randomized, placebo-controlled trial in
which 89 patients with LAM who had moderate lung impairment
were assigned to either sirolimus (also known as rapamycin) or
placebo for 1 year, followed by a 1-year observation period. Their
study demonstrated that treatment with sirolimus for 1 year
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Figure 2. Effects of Rapamycin in Various
Diseases
A growing body of evidence has demonstrated
that, though limited, rapamycin or rapalogs are
beneficial for treating various diseases including
cancer, diabetes, tuberous sclerosis complex,
LAM, neurodegenerative diseases, and aging.
FDA-approved cases are described.
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with LAM.However, once patients stopped taking sirolimus, their
lung function deteriorated again. The authors concluded that
additional trials are required to investigate the duration of treat-
ment and long-term safety of sirolimus (McCormack et al.,
2011). Approximately 80%of all TSCpatients and 50%ofwomen
with LAM also develop angiomyolipomas (AMLs), which are
benign tumors of the kidney. Bissler et al. conducted two sepa-
rate trials to evaluate the use of sirolimus or everolimus for AML
in TSC or LAM. Their results showed that sirolimus or everolimus
decreased AML volume (Bissler et al., 2008, 2013). However, the
tumors returned to their original states when sirolimus was dis-
continued, underscoring the cytostatic and not cytotoxic effects
of rapamycin and rapalogs. Since rapamycin-based therapy sup-
presses immune function and may cause serious side effects
such as thrombocytopenia and hyperlipidemia, impaired wound
healing, nephrotoxicity, and altered insulin sensitivity, the safety
of long-term use still remains uncertain.
A growing body of evidence suggests that the mTORC1
pathway may also be involved in a number of neurological disor-
ders. For instance, patients with TSC are prone to a wide range
of neurological diseases, such as epilepsy, neurocognitive
dysfunction, and autism. Therefore, inhibition of mTORC1 is a
potential therapeutic option. In a mouse model of TSC, rapamy-
cin treatment was shown to suppress epilepsy, and shortly after,
the study by Muncy et al. demonstrated that rapamycin reduced
seizure frequency in a 10-year-old girl with TSC (Muncy et al.,
2009). A recent study by Sato et al. reported that rapamycin re-
verses impaired social interactions associated with autism spec-
trum disorder in a mouse model of TSC. Their data suggested
that the abnormal behaviors displayed by TSC-deficient mice
were correlated with altered gene and protein expressions
involved in the mTOR signaling (Sato et al., 2012). In 2012, the
FDA approved the use of everolimus for the treatment of patients
with TSC who have subependymal giant cell astrocytoma
(SEGA), a neurological manifestation of TSC. Currently, there is
an ongoing phase two trial assessing the possible neurocogni-Cell Metabolismtive benefits from treatment with everoli-
mus (NCT01289912). Future therapies
involving the use of ATP-competitive
mTOR inhibitors alone or in combinations
with other drugs, such as estrogen antag-
onists, are being explored for the treat-
ment of LAM.
Finally, a number of studies have indi-
cated that pharmacological inhibition of
mTORC1 can provide neuroprotection
in several in vivo models of neurodegen-
erative diseases, including Alzheimer’sdisease, Parkinson’s disease, Huntington’s disease, and spino-
cerebellar ataxia type 3 (Bove et al., 2011). Mounting evidence
suggested that accumulation of misfolded and aggregated pro-
teins is a common feature of these diseases, possibly caused by
mTORC1-driven protein synthesis and defective autophagic
degradation. Thus, suppression of protein synthesis and induc-
tion of autophagy by rapamycin may prevent or diminish protein
aggregation. Moreover, a recent study has shown that rapamy-
cin improves survival and attenuates disease progression in a
mouse model (Ndufs4/) of Leigh syndrome, which is a neuro-
logical disorder characterized by a genetic defect that disrupts
mitochondrial function (Johnson et al., 2013b). For more detailed
descriptions of the molecular mechanisms underlying how rapa-
mycin exerts its neuroprotective effect, we refer the readers to a
comprehensive review (Bove et al., 2011) (Figure 2).
Effects of Rapamycin on Longevity and Aging
mTOR signaling is an important player in longevity regulation.
Genetic or pharmacological inhibition of mTOR signaling has
been found to extend lifespan of invertebrates including yeast,
nematodes, and fruit flies (Lamming et al., 2013). In 2009, Harri-
son et al. showed that rapamycin extends both median and
maximal lifespan of male and female genetically heterogeneous
mice when beginning treatment at 9 or 20 months of age (1.5–2
year duration) (Harrison et al., 2009), representing the first
demonstration in mammals. Subsequent work by other groups
confirmed the positive effect of rapamycin on lifespan in mice
with different genetic backgrounds and other model organisms
(Lamming et al., 2013). Two classes of explanations may ac-
count for these observations: (1) rapamycin increases lifespan
by slowing aging, or (2) rapamycin inhibits detrimental metabolic
diseases or lethal neoplastic diseases, independent of aging ef-
fects. To test the hypothesis that rapamycinmight retard aging in
mice, Wilkinson et al. used a genetically heterogeneous mouse
model and analyzed a number of age-related pathologies as
well as age-dependent spontaneous activity of mice upon rapa-
mycin treatment beginning at 9 months of age (1 year duration).19, March 4, 2014 ª2014 Elsevier Inc. 375
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more slowly in rapamycin-treated mice, including alterations in
heart, liver, endometrium, adrenal gland, and tendon elasticity.
Rapamycin was also shown to diminish age-related decline in
spontaneous activity of mice (Wilkinson et al., 2012).
As rapamycin is known to have modest antiproliferative prop-
erties in many forms of cancer, lifespan extension by rapamycin
could also be caused by suppression of specific life-limiting pa-
thologies (e.g., cancer). In a recent article by Neff et al. (2013),
several concerns were raised with regard to the previous reports
on the effect of rapamycin in slowing aging. For example, cancer
is themain cause of death in mice, including themice strain used
in the study by Wilkinson et al. (2012). In addition, aging-inde-
pendent effects by rapamycin were not examined previously.
In the study by Neff et al. (2013), the authors dosed male
C57BL/6j mice with rapamycin or vehicle control for 1 year
at three different treatment onsets: young adulthood (i.e., at
4 months), midlife (i.e., at 13 months), and late in life (i.e., at
20–22 months). After completing the treatment, they performed
a large assessment of diverse structural and functional aging
phenotypes in a variety of cell types, tissues, and organ systems.
Intriguingly, while rapamycin did extend lifespan in mice, age-
related traits were largely unaffected. Although rapamycin was
able to rescue a subset of aging-dependent phenotypes, such
as spatial learning and memory impairments, as well as declined
exploratory activity, similar positive effects on many of these
attributes were also observed in young mice, indicating an
age-independent effect. They reasoned that the discrepancy in
findings could be due to different mouse models (genetic back-
grounds) used in the studies or technical variations in the anal-
ysis (Neff et al., 2013), which, however, were challenged by
Blagosklonny (Blagosklonny, 2013). Clearly, future studies with
other mouse strains and gender are warranted (Figure 2).
Effects of Rapamycin on Metabolism
In response to nutrients and growth factors, mTOR signaling
serves as a key regulator of cell metabolism to coordinate the
balance between anabolic and catabolic processes. When
fasting, muscle and liver produce glucose via glycogenolysis
(glycogen breakdown) and gluconeogenesis (glucose synthesis),
and adipose tissue generates fatty acids through lipolysis,
whereas, upon feeding, glycogenesis (glycogen synthesis) is
favored inmuscle and liver, and lipid uptake is favored in adipose
tissue. Dysregulation of mTOR signaling has been linked to
the development of a few metabolic diseases, such as diabetes
and obesity (Laplante and Sabatini, 2012). Inhibition of themTOR
pathway by rapamycin has been demonstrated to have both
beneficial and detrimental effects on metabolism. For example,
acute rapamycin treatment improves insulin sensitivity in vitro
and in vivo by disrupting a S6K-mediated feedback loop
(described below) (Krebs et al., 2007; Tremblay and Marette,
2001). Moreover, rapamycin treatment inhibits human adipocyte
differentiation in vitro (Bell et al., 2000) and protects against high-
fat-diet-induced obesity in C57BL/6J mice (16 weeks) (Chang
et al., 2009a). As discussed above, rapamycin appears capable
of extending the lifespan of mice and preventing the onset of
many age-related diseases; however, deleterious metabolic
effects associated with rapamycin were also reported in other
studies. For instance, Fraenkel et al. found that rapamycin treat-376 Cell Metabolism 19, March 4, 2014 ª2014 Elsevier Inc.ment (2 weeks) worsened hyperglycemia in a nutrition-depen-
dent type 2 diabetes mouse model (Fraenkel et al., 2008).
Similarly, the study by Chang et al. demonstrated that rapamycin
administration (6 weeks) exacerbates glucose intolerance in
diet-induced obesity KK/HIJ mice (Chang et al., 2009b). More-
over, the study by Houde et al. reported that rapamycin treat-
ment (2 weeks) promoted insulin resistance and hyperlipidemia
in rats (Houde et al., 2010). It is currently unclear how rapamycin
can have both positive and negative effects. In 2012, Lamming
et al. showed that rapamycin exerts different effects via separate
mechanisms. They found that while reducedmTORC1 increases
longevity and maintains normal glucose homeostasis, disruption
of mTORC2 contributes to insulin resistance in vivo (Lamming
et al., 2012). Additionally, Fang and colleagues suggested that
these seemingly controversial findings might be explained by
the duration of rapamycin treatment (Fang et al., 2013). Their
study compared various metabolic effects in male mice after 2,
6, or 20 weeks of rapamycin treatment. After 2 weeks of rapamy-
cin treatment, themice displayed smaller pancreas and enlarged
liver. However, with prolonged treatment, these features re-
turned to normal levels, while adiposity, body weight (BW), and
food consumption were significantly reduced. More strikingly,
insulin sensitivity was altered with respect to different lengths
of rapamycin treatment. Under normal physiological conditions,
insulin suppresses hepatic gluconeogenesis while increasing
lipogenesis, but in individuals with impaired insulin sensitivity,
excess insulin is secreted to compensate for the insulin resis-
tance. In agreement with previous findings by Houde et al.
(2010), insulin levels were increased after 2 weeks of rapamycin
treatment, and the treated mice became glucose intolerant and
insulin resistant. Interestingly, after 6 weeks of treatment the
mice exhibited a transition to improved insulin sensitivity and
by 20 weeks of rapamycin treatment insulin levels were
decreased while insulin sensitivity increased. Additional meta-
bolic effects including lipid profile, oxygen consumption, and
ketogenesis were also altered in a manner relative to treatment
durations (Fang et al., 2013). Together, these remarkable find-
ings may provide insight into how long-term treatment of rapa-
mycin extends longevity in mice. However, how these studies
will translate to human aging is unclear (Figure 2).
Limitations of Monotherapy
The beneficial effects of rapamycin have largely been shown in
preclinical animal models. However, the clinical success of rapa-
mycin has been associated with only a few benign andmalignant
cancers. Several factors may contribute to the modest outcome
in the clinic. (1) Rapamycin and rapalogs are generally cytostatic
instead of cytotoxic. Clinical trials have demonstrated that
while rapamycin treatment can induce tumor regression, tumors
regrow upon the cessation of treatment (Bissler et al., 2008;
Marsh et al., 2008). (2) Rapamycin fails to completely inhibit a
subset of mTORC1-mediated processes, such as protein syn-
thesis and autophagy. Choo et al. reported that rapamycin differ-
entially regulates S6Ks versus 4E-BP1. In several cell types,
short-term treatment of rapamycin dephosphorylates 4E-BP1;
however, phosphorylation of 4E-BP1 remerges after 12+ hr
treatment, resulting in a recovery in cap-dependent translation
despite continued inhibition of S6K (Choo et al., 2008). In addi-
tion, although it was known that rapamycin effectively activates
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Figure 3. Many Negative Feedback Loops in mTOR Signaling
(A) When mTORC1 is active, Akt activation is attenuated by inhibition of the RTK-PI3K signaling pathway through multiple mechanisms including inhibitory
phosphorylation events on IRS by mTORC1 or S6K1 and Rictor by S6K1, and stimulation of inhibitory adaptor protein Grb10 by mTORC1.
(B) Rapamycin relieves negative feedback loops and promotes activation of PI3K signaling. The inhibition of mTORC1 by rapamycin reduces themTORC1-driven
negative feedback effects and thus activates the PI3K-Akt pathway and promotes cell survival. Additionally, partial inhibition of mTORC1 substrates by rapa-
mycin such as 4E-BP1 may also contribute to cell survival.
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mammalian cells (Thoreen and Sabatini, 2009). These partial
inhibitory effects may offer a potential explanation for the poor
efficacy of rapamycin in clinical trials. However, it is puzzling
why mTORC1 substrates have differential sensitivities to rapa-
mycin treatment in cells. In a recent study, Kang and colleagues
found that mTORC1 phosphorylation sites are one determinant
for the differential responses to rapamycin. It was shown that
the ability of mTORC1 to phosphorylate a specific site in vitro
has a strong correlation with the respective rapamycin-resistant
site in cells. For example, mTORC1 potently phosphorylated the
synthetic peptides encompassing 4E-BP1 (T37) and (T46), which
are rapamycin resistant. In contrast, mTORC1weakly phosphor-
ylated S6K1 (T389), which is rapamycin sensitive. Furthermore,
their findings indicated that the sequence composition of
mTORC1 phosphorylation sites is one essential factor in deter-
mining substrate quality within cells. Lastly, Kang et al. were
able to control mTORC1 activity toward a substrate phosphory-
lation site in vitro, and subsequently alter substrate sensitivity to
rapamycin, nutrient, and growth factor levels in cells as well
(Kang et al., 2013). (3) Another reason for the limited clinical
success of rapalogs is the existence of several feedback loops
involved in cell survival responses. For instance, under normal
circumstances, mTORC1-mediated activation of S6K1 pro-
motes degradation of insulin receptor substrate (IRS) and sub-
sequent downregulation of PI3K signaling. Inhibition of mTORC1
by rapamycin relieves this negative feedback loop, thereby
increasing PI3K signaling. Likewise, mTORC1-mediated
signaling via S6K1 also inhibits mTORC2 by phosphorylation of
Rictor. Rapamycin blocks this feedback loop, resulting in
mTORC2-mediated AKT activation. Additionally, mTORC1
negatively regulates growth factor receptor-bound protein 10
(Grb10), an inhibitor of PI3K signaling. Thus, rapamycin released
mTORC1-mediated inhibition of Grb10, leading to PI3K pathway
activation in certain cell types (Laplante and Sabatini, 2012)(Figure 3). (4) Recent studies also demonstrate that inhibition
of PI3K/AKT/mTOR pathway can lead to reactivation of many
RTKs and their downstream signaling systems (Chandarlapaty
et al., 2011). (5) Compensatory pathways exist that are often
activated in cancer cells or upregulated in response to chronic
rapamycin treatment (discussed above). For example, other
AGC kinase family members can compensate for S6K1 inhibition
such as RSK and Akt (Mendoza et al., 2011). (6) Finally, eIF4E
expression can be upregulated with chronic inhibition of mTOR
(Alain et al., 2012). One of the major unanswered questions in
the field is why these various compensatory mechanisms and
negative feedback loops are differentially regulated in different
organisms or in different cancer cell types. Fully addressing
this question will lead to an improved understanding as to why
rapalogs work better in some cases than in others, and that
should lead to improved therapeutic responses with mTOR
inhibitors in monotherapy or combination therapy.
Rapamycin in Combination Therapy
Themodest effect of rapamycin-based therapy has prompted in-
vestigators to consider other therapeutic options. Combination
therapy with rapamycin or rapalogs has become a promising
approach, as various strategies have the potential of improving
drug efficacy by inhibiting multiple targets including those acti-
vated by removal of feedback loops or those involved in parallel
pathways. Additionally, combination approaches may delay the
emergence of drug resistance.
In 2012, everolimus was approved by the FDA in combination
with exemestane (aromatase inhibitor) for the treatment of post-
menopausal women with advanced hormone receptor-positive
HER2-negative breast cancer who experience recurrence
or progression after treatment with letrozole or anastrozole
(aromatase inhibitors) alone. In addition, multiple clinical trials
are currently evaluating the efficacy of rapalogs with several
chemotherapeutic agents, including paclitaxel, doxorubicin,Cell Metabolism 19, March 4, 2014 ª2014 Elsevier Inc. 377
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gested that rapalogs work effectively with targeted therapies to
enhance antitumor activity, such as RTK-targeted therapy, hor-
mone-based therapy, angiogenesis inhibitors, and IGF-IR inhib-
itor. For example, the combination of rapamycin and erolitinib
(epidermal growth factor receptor [EGFR] inhibitor) resulted in
a synergistic effect in vitro and significantly reduced tumor
growth in vivo compared to single-agent treatment. This may
be linked to the activation of RTKs by inhibition of the PI3K/
Akt/mTOR pathway (Chandarlapaty et al., 2011). In addition, a
phase one trial examined the combination of everolimus with
pasireotide, a somatostatin analog, in patients with advanced
neuroendocrine tumors. The preliminary data showed that the
combination induced antitumor activity, and further studies are
underway (Zaytseva et al., 2012). Furthermore, everolimus was
shown to potently inhibit growth in many tumor types with acti-
vated mTOR in combination with lower doses of the catalytic
mTOR inhibitor BEZ235, used to reduce survival via feedback
loops activating Akt (Nyfeler et al., 2012). Many more clinical
trials are currently investigating different combination ap-
proaches. Exciting outcomes from these studies are anticipated
in the near future.Conclusion and Future Perspective
Since the serendipitous discovery of rapamycin, considerable
achievements have beenmade in understanding themechanism
of action and unraveling the intricate signaling network of mTOR.
Uncontrolled mTORC1-mediated signaling is often observed in
human diseases. Therefore, it was thought that pharmacological
inhibition of mTOR by rapamycin would have a substantial
and wide range of clinical effects. Although rapamycin-based
therapy has shown benefits for patients with RCC-, TSC-, and
LAM-related tumors, the use of rapamycin monotherapy in a
broad spectrum of metabolic diseases, especially in treating
cancers, is limited due to its modest efficacy. This may be
explained by the inability of rapamycin to completely block
mTORC1-mediated signaling events, the presence of several
feedback loops, and the upregulation of compensatory path-
ways that promote cell survival and growth. Thus, there is a crit-
ical need to further define these signaling processes and to
develop new strategies that can overcome these drawbacks.
The recent emergence of combination therapy with rapamycin
may further increase efficacy and bypass feedback activation
of survival pathways. Efforts that focus on exploring novel drug
combinations with optimal doseswill have great potential to yield
an improvement of efficacy and safety profiles. Additionally,
significant promise remains for the discovery of new pathway in-
hibitors as well as the possibility that existing bioactives may
directly or indirectly reduce mTORC1 and/or mTORC2 activity
in monotherapy or in combination.ACKNOWLEDGMENTS
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